Trial Profile
Phase I/II Study of Lenalidomide and Ofatumumab for the Treatment of Relapsed or Refractory Non-Hodgkin's Lymphoma.
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 06 Oct 2023
Price :
$35
*
At a glance
- Drugs Lenalidomide (Primary) ; Ofatumumab (Primary)
- Indications Follicular lymphoma; Non-Hodgkin's lymphoma
- Focus Adverse reactions
- 20 Feb 2019 Status changed from active, no longer recruiting to completed.
- 01 Sep 2017 Planned primary completion date changed from 1 Dec 2016 to 1 Dec 2017.
- 19 Apr 2016 Planned primary completion date changed from 1 Jan 2016 to 1 Dec 2016.